Vun-Sin Lim, PhD

Managing Editor of the Journal of Thoracic Oncology | Tweets are my own | Bluesky handle:

[Vun-Sin Lim, PhD @vs_lim]

#WCLC25 It takes a village!

Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @IASLC!

@DrAlexAdjei @JTOonline @ElsevierConnect #JTO #JTOCRR

[JTO & JTO CRR @JTOonline]

JTO's success is made possible by leaders like Michele Carbone.

We are grateful for your six years of service and impact! #JTO20

[JTO & JTO CRR @JTOonline]

Former Managing Editor Mary Todd reflects on JTO’s 20th anniversary and thanks the editors, authors, reviewers, and publishers who have helped advance science and patient care along the way.

#JTO20 #ThoracicOncology #IASLC

[Vun-Sin Lim, PhD @vs_lim]

Behind the scenes of JTO Insights Podcast Ep. 6: we've got both Editors-in-Chief in the house!

EICs #JTO @DrAlexAdjei & #JTOCRR Emily Stone w/ co-host @TommyJohn00 & podcast team Laura Woodruff @CMPR

📆Tune in on June 25
🔗https://t.co/DOycZiO67w

#JTO20 @IASLC @JTOonline

[Hidehito HORINOUCHI @HHorinouchi]

🔥FAK/SRC pathway adaptive signaling drives KRAS G12C inhibitor resistance
🆙 @JTOonline @IASLC
🎯FAK/SRC inhibitors synergize with KRAS inhibitors & resensitize resistant cells in preclinical models
🎙Dr. Hibiki Udagawa
#LCSM @On@OncoAlert @Larvol @KRASKickers
https://t.co/k0Bt7tZXOv

[Hidehito HORINOUCHI @HHorinouchi]

🔥DART study: ctDNA-based MRD detection in stage III NSCLC treated with CRT + durvalumab
🆙 @JTOonline
🎯Detectable ctDNA at cycle 7 & post-Tx⏩inferior PFS (HR 2.45, 5.37)
🎙Dr. Henrik Horndalsveen @HellandAslaug
#LCSM @OncoAlert @Larvol #Liquidbiopsy
https://t.co/BrUIBIc8nR

[JTO & JTO CRR @JTOonline]

Advancing science requires collaboration, expertise, and dedication.

Thank you to Myung-Ju Ahn for seven years of service to JTO! #JTO20

[Jarushka Naidoo @DrJNaidoo]

T-5 days until the @IASLC Hot Topics Meeting on Immunotherapy Resistance in Dublin ☘️

Join us for 2 days of top-class learning at the famous @tcddublin. IASLC membership free for students & trainees

Register here 👉🏻https://t.co/2hCq3peI6n
discount code 👉🏻15FORDE

[Hidehito HORINOUCHI @HHorinouchi]

🔥Amivantamab induces immune-mediated cytotoxicity in mesothelioma via EGFR/MET
🆙 @JTOonline
🎯Ami + NK cells reduced tumor growth in PDX without overt toxicity
🎙Dr. Shinichiro Suzuki @kaushalpar @AMansfieldMD
#LCSM @OncoAlert @Larvol @EGFRResisters @metcrusaders
https://t.co/OTCEUgAt0H

[JTO & JTO CRR @JTOonline]

Great journals are built by dedicated leaders.

Thank you to Anne-Marie Dingemans for seven years of contributions to JTO! #JTO20

[JTO & JTO CRR @JTOonline]

Thank you to the global thoracic oncology community for publishing, reviewing, reading, and citing this research. Join us at #WCLC26 as we celebrate the 20th Anniversary of JTO and the community behind its impact.
#JTO20 #ThoracicOncology #CancerResearch

[JTO & JTO CRR @JTOonline]

As we celebrate #JTO20, we recognize @TommyJohn00 for eight years of service and commitment to scientific excellence.

Thank you for your dedication to the Journal!

[Stephen V Liu, MD @StephenVLiu]

AURORA-ROS1 real world registry from Australia: ROS1 in 2.2% of NSCLC, median age 58, 64% female, 85% advanced at diagnosis, 14% with brain mets. Across lines, 96% received a ROS1 TKI, 53% on a clinical trial, mPFS 48m with 1L later generation TKIs.

https://t.co/QM8haroQHo

[Stephen V Liu, MD @StephenVLiu]

With immunotherapy in NSCLC, long term outcomes remain relevant. 5y update on phase III EMPOWER-Lung 3 trial of 1L chemo +/- cemiplimab @JTOonline: OS 21 vs 13m (HR 0.66); 5y OS rate 19.4% with cemiplimab vs 8.8%. PFS 8.2 vs 5.5m; HR 0.58, RR 44% vs 22%.

https://t.co/v763rIB7VI

[Eric K. Singhi, MD @lungoncdoc]

Our new @JTOonline publication led by @alvaroonco

After progression on RET inhibitors, continuing RET inhibition + chemo may outperform chemoIO:
▫️PFS: 7.8 v 3.5 mo (HR 0.24)
▫️ORR: 38% v 25%

More hematologic toxicity, but encouraging strategy that warrants prospective study.

[JTO & JTO CRR @JTOonline]

Today we celebrate Emily Stone, whose seven years of service helped strengthen JTO and support progress in thoracic oncology. Thank you Emily for your service to the Journal! #JTO20

[JTO & JTO CRR @JTOonline]

Years of commitment make a difference. Thank you to Ross Camidge for 9 years with JTO. We appreciate your service to the Journal! #JTO20

[JTO & JTO CRR @JTOonline]

In this study, Zanghì et al. used peripheral blood mononuclear cell profiling to personalize LDCT screening intervals to combat false positives and increase accuracy.
📑Read more: https://t.co/russfbk5bF
@IstTumori

[JTO & JTO CRR @JTOonline]

🎧 In the latest #JTOInsights, Drs. @DrAlexAdjei and @TommyJohn00 are joined by Drs. Natasha B. Leighl and Gabriella Sozzi to discuss plasma ctDNA in high-risk stage I #NSCLC and improving lung cancer screening accuracy. Listen now: https://t.co/gOut1LAkZh

[IASLC @IASLC]

The global #lungcancer community is heading to Seoul for #WCLC26.

Take advantage of Early Bird pricing before June 12 and be part of four days of cutting-edge science, collaboration, and multidisciplinary learning.

Register today: https://t.co/pFJaBKvqSA

[Herbert Loong, MBBS, FASCO @herbloong]

Thanks @SCMPNews for their coverage on the increasing incidence of #lungcancer 🫁 amongst people who have never smoked esp. in #women in #hongkong 🇭🇰 and the #AsiaPacific 🌏 region. This is an emerging and urgent #publichealth issue that warrants coordinated #action by all #stakeholders.

Incidentally - the title and the picture is a bit misleading. I am merely a #messenger, not a #killer 🤣🤪😝!

@APCLC_2023 @apoddc @CUHKMedicine @IASLC @LungPolicy #LCSM